Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Avidity Biosciences

    Client Virtual Booth

    AVIDITY BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Avidity Biosciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10975 N. Torrey Pines Rd. Suite 150 La Jolla, CA 92037
    Telephone
    Telephone
    858-401-7900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aviditybiosciences.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/avidity-biosciences-llc
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Avidity Bio Announces Nasdaq Inducement Grants
    Avidity Bio Announces Nasdaq Inducement Grants

    https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302123521.html

    PR NEWSWIRE
    22 Apr 2024
    Share Share
    Avidity Biosciences to Participate in Upcoming Investor Conferences
    Avidity Biosciences to Participate in Upcoming Investor Conferences

    https://aviditybiosciences.investorroom.com/2024-03-27-Avidity-Biosciences-to-Participate-in-Upcoming-Investor-Conferences

    PRESS RELEASE
    27 Mar 2024
    Share Share
    Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Avidity Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302096215.html

    PR NEWSWIRE
    21 Mar 2024
    Share Share
    Avidity accelerates DM1 Phase III trial on the heels of further positive data
    Avidity accelerates DM1 Phase III trial on the heels of further positive data

    https://aviditybiosciences.investorroom.com/2024-03-04-Avidity-Biosciences-Announces-Positive-AOC-1001-Long-term-Data-Showing-Reversal-of-Disease-Progression-in-People-Living-with-Myotonic-Dystrophy-Type-1-Across-Multiple-Endpoints-Same-Key-Endpoints-Agreed-for-Phase-3-HARBOR-TM-Trial

    PRESS RELEASE
    04 Mar 2024
    Share Share
    Avidity Biosciences Announces Positive AOC 1001 Long-term Data
    Avidity Biosciences Announces Positive AOC 1001 Long-term Data

    https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-aoc-1001-long-term-data-showing-reversal-of-disease-progression-in-people-living-with-myotonic-dystrophy-type-1-across-multiple-endpoints-same-key-endpoints-agreed-for-phase-3-harbor-trial-302078020.html

    PR NEWSWIRE
    04 Mar 2024
    Share Share
    Avidity Biosciences Honors Rare Disease Day®
    Avidity Biosciences Honors Rare Disease Day®

    https://www.prnewswire.com/news-releases/avidity-biosciences-honors-rare-disease-day-302075366.html

    PR NEWSWIRE
    29 Feb 2024
    Share Share
    Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
    Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

    https://aviditybiosciences.investorroom.com/2024-02-29-Avidity-Biosciences-Announces-Oversubscribed-400-Million-Private-Placement

    PRESS RELEASE
    29 Feb 2024
    Share Share
    Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044
    Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044

    https://www.prnewswire.com/news-releases/avidity-biosciences-receives-fda-rare-pediatric-disease-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-in-people-with-mutations-amenable-to-exon-44-skipping-302065520.html

    PR NEWSWIRE
    20 Feb 2024
    Share Share
    Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data
    Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data

    https://www.prnewswire.com/news-releases/avidity-biosciences-to-present-new-aoc-1001-long-term-efficacy-and-safety-data-from-marina-ole-trial-in-people-living-with-myotonic-dystrophy-type-1-dm1-at-2024-muscular-dystrophy-association-mda-clinical--scientific-confere-302063559.html

    PR NEWSWIRE
    15 Feb 2024
    Share Share
    Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Avidity Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302041105.html

    PR NEWSWIRE
    22 Jan 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search